Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

A Phase II Study of Bortezomib in Combination With Dexamethasone in Patients With Relapsed Hodgkin's Lymphoma

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

The proteasome-inhibitor bortezomib (Velcade) shows promising activity in various human lymphoma cell line. In addition, several studies in heavily pretreated patients with lymphoma showed also promising results.

Inclusion Criteria:

• Hodgkin's lymphoma
• Second or higher relapse (first relapse if high-dose chemotherapy not possible)
• Age >/= 18 years
• No major organ dysfunction or intercurrent disorder
• Written informed consent

Exclusion Criteria:

• Pregnant or nursing